NCT02240719View on ClinicalTrials.gov

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 9, 2018

Study Completion Date

April 9, 2018

Conditions
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaMultiple Myeloma
Interventions
DRUG

everolimus

Given PO

DRUG

bendamustine hydrochloride

Given IV

Trial Locations (1)

95817

University of California Davis, Sacramento

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, Davis

OTHER